HKUMed cracks gastric cancer’s ‘metabolic code’: Tumour growth slowed by 65%, plus a 6.3-fold kill rate with cholesterol inhibitors in neuron-infiltrated cases
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Dec-2025 20:11 ET (22-Dec-2025 01:11 GMT/UTC)
Scientists have developed a new computational tool that maps multi-gene pathways more comprehensively than ever before.
The study uncovered a previously unknown protein pathway that, when blocked, kills blood cancer cells.
The discovery could lead to new therapies for patients with drug-resistant blood cancers.In a special 11 December event for science journalists, the Science Press Package team will revisit the topic recognized as Science’s Breakthrough of the year in 2023: the development of GLP-1 receptor agonists to treat obesity and their efficacy in blunting obesity-associated health problems. The Mani L. Bhaumik Breakthrough of the Year Award that the American Association for the Advancement of Science, publisher of Science, gave to researchers whose work best underpinned the GLP-1 breakthrough was steered by a committee that included Dr. Katherine Saunders, obesity physician at Weill Cornell Medicine and co-founder of FlyteHealth. Dr. Saunders routinely works with media, responding to questions about how GLP-1s are prescribed as part of comprehensive cardiometabolic care. She recognizes opportunities for news stories on such topics to more accurately reflect the realities of the biology of obesity as a disease, and the science taken into account when treating patients with GLP-1s.
In this briefing, Dr. Saunders will take your questions on these topics. She will be joined by Dr. Robyn Pashby, a clinical health psychologist specializing in obesity-related behavioral science, and Dr. Tracy Zvenyach, a health policy researcher and Director of Policy Strategy at the Obesity Action Coalition. Dr. Pashby will discuss topics including the neurobehavioral links between mental health and obesity, and how GLP-1 medications influence motivation, reward processing, and treatment engagement. Dr. Tracy Zvenyach, who engages in policy advocacy and research to improve access to obesity treatments, will outline the coverage landscape, including how standard health insurance is working, and how it isn’t. She will also discuss policy implications of continued research into GLP-1s, which show a growing range of benefits.
The event was held on Thursday 11 December on Zoom. A recording of the briefing is available at https://aaas.zoom.us/rec/share/IclD5PYqvNWyBwWnFTDHU6MzwhOutQIGKcLvS39_wBlUmeJ2zddWPyRBqoUqEX-3.4Z_u1VPXnfBjp5Yp; the passcode is 3!feGKJZ
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.
Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated.
The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.
Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.
Fatty liver disease, hepatitis, hepatocellular carcinoma (HCC), and other major liver diseases are significant global public health challenges. Understanding what drives these diseases and exploring targeted therapies is of critical importance. Recently, in the journal Science China Life Sciences, a team from Shandong Second Medical University in collaboration with Shanghai Jiao Tong University published an online review titled "Deubiquitinases in liver diseases: from mechanisms to targeted therapy". This review systematically elucidates the central roles and therapeutic advances related to deubiquitinases (DUBs) in various liver diseases.